Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Jun 20;39(18):1971-1982.
doi: 10.1200/JCO.20.03502. Epub 2021 Apr 27.

National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide

Bronwen E Shaw  1 , Antonio Martin Jimenez-Jimenez  2 , Linda J Burns  1 , Brent R Logan  1 , Farhad Khimani  3 , Brian C Shaffer  4 , Nirav N Shah  5 , Alisha Mussetter  6 , Xiao-Ying Tang  1 , John M McCarty  7 , Asif Alavi  8 , Nosha Farhadfar  9 , Katarzyna Jamieson  10 , Nancy M Hardy  11 , Hannah Choe  12 , Richard F Ambinder  13 , Claudio Anasetti  3 , Miguel-Angel Perales  4 , Stephen R Spellman  6 , Alan Howard  6 , Krishna V Komanduri  2 , Leo Luznik  13 , Maxim Norkin  14 , Joseph A Pidala  3 , Voravit Ratanatharathorn  8 , Dennis L Confer  6 , Steven M Devine  6 , Mary M Horowitz  1 , Javier Bolaños-Meade  13
Affiliations
Clinical Trial

National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide

Bronwen E Shaw et al. J Clin Oncol. .

Abstract

Purpose: Hematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors. Despite unrelated donor registries listing > 38 million volunteers, 25%-80% of US patients lack an HLA-matched unrelated donor, with significant disparity across ethnic groups. We hypothesized that HCT with a mismatched unrelated donor (MMUD) using post-transplant cyclophosphamide (PTCy), a novel strategy successful in overcoming genetic disparity using mismatched related donors, would be feasible and increase access to HCT.

Patients and methods: We performed a prospective phase II study of MMUD bone marrow HCT with PTCy for patients with hematologic malignancies. The primary end point was 1-year overall survival (OS), hypothesized to be 65% or better. 80 patients enrolled at 11 US transplant centers (December 2016-March 2019). Following myeloablative or reduced-intensity conditioning-based HCT, patients received PTCy on days +3, +4, with sirolimus and mycophenolate mofetil starting on day +5. We compared outcomes to Center for International Blood and Marrow Transplant Research contemporary controls receiving PTCy.

Results: Notably, 48% of patients enrolled were ethnic minorities. 39% of pairs were matched for 4-6 out of 8 HLA alleles. The primary end point was met, with 1-year OS of 76% (90% CI, 67.3 to 83.3) in the entire cohort, and 72% and 79% in the myeloablative and reduced-intensity conditioning strata, respectively. Secondary end points related to engraftment and graft-versus-host-disease were reached. Multivariate analysis comparing the study group with other mismatched HCT controls found no significant differences in OS.

Conclusion: Our prospective study demonstrates the feasibility and effectiveness of HCT with an MMUD in the setting of PTCy. Remarkably, nearly half of the study participants belonged to an ethnic minority population, suggesting this approach may significantly expand access to HCT.

Trial registration: ClinicalTrials.gov NCT02793544.

PubMed Disclaimer

Conflict of interest statement

Bronwen E. ShawHonoraria: TherakosConsulting or Advisory Role: Orca Bio Brent R. LoganConsulting or Advisory Role: Daiichi Sankyo, Enlivex Therapeutics Ltd, Gamida Cell Farhad KhimaniResearch Funding: Bristol Myers Squibb Brian C. ShafferConsulting or Advisory Role: Hansa BiopharmaResearch Funding: Miltenyi Biotec Nirav N. ShahStock and Other Ownership Interests: Exelixis, GeronHonoraria: Miltenyi Biotec, Loxo/LillyConsulting or Advisory Role: Kite, a Gilead company, Celgene, Verastem, Loxo/Lilly, Legend Biotech, TG Therapeutics, EpizymeResearch Funding: Miltenyi BiotecTravel, Accommodations, Expenses: Miltenyi Biotec Alisha MussetterResearch Funding: Magenta Therapeutics Inc Xiao-Ying TangResearch Funding: Jazz Pharmaceuticals, OncoImmune, Gamida Cell, Merck, Kyowa Kirin International, Bristol Myers Squibb John M. McCartyHonoraria: Kite, a Gilead company, Anthem WellpointResearch Funding: Celgene/Bristol Myers Squibb, Celgene, FATE Therapeutics, Seattle Genetics Nosha FarhadfarConsulting or Advisory Role: IncyteResearch Funding: CSL Behring Nancy M. HardyConsulting or Advisory Role: Kite, a Gilead company, Gilead Sciences, American Gene TechnologiesResearch Funding: Incyte, TakedaTravel, Accommodations, Expenses: Kite/GileadUncompensated Relationships: GPB Claudio AnasettiStock and Other Ownership Interests: Ionis PharmaceuticalsHonoraria: Gilead SciencesConsulting or Advisory Role: Gilead Sciences Miguel-Angel PeralesStock and Other Ownership Interests: NexImmuneConsulting or Advisory Role: Incyte, Merck, Servier/Pfizer, NexImmune, Novartis, MolMed, Medigene, Takeda, Nektar, Abbvie, Cidara Therapeutics, Celgene, Kite/Gilead, Bristol Myers Squibb, OmerosResearch Funding: Incyte, Miltenyi Biotec, Novartis Krishna V. KomanduriHonoraria: Takeda, Kadmon, Kite/Gilead, Kiadis Pharma, Novartis, Incyte, AutolusConsulting or Advisory Role: Kiadis Pharma, Kite/Gilead, Novartis, Takeda, Incyte, Autolus, Kadmon, Genentech/Roche, Iovance Biotherapeutics, Gamida CellExpert Testimony: Kite/Gilead Leo LuznikConsulting or Advisory Role: Gilead Sciences, Talaris Therapeutics, Precision BioSciences, Rubius Therapeutics, WindMIL TherapeuticsResearch Funding: Genentech, AmgenPatents, Royalties, Other Intellectual Property: Patent holder WindMIL TherapeuticsUncompensated Relationships: WindMIL Therapeutics Maxim NorkinResearch Funding: Celgene Joseph A. PidalaConsulting or Advisory Role: Syndax, CTI BioPharma Corp, Amgen, Regeneron Steven M. DevineHonoraria: Kiadis PharmaConsulting or Advisory Role: Bristol Myers SquibbResearch Funding: Orca Bio, Kiadis PharmaTravel, Accommodations, Expenses: Orca Bio Mary M. HorowitzConsulting or Advisory Role: Magenta Therapeutics, Janssen Research & Development, MedacResearch Funding: Biovitrum, Jazz Pharmaceuticals, Magenta Therapeutics, Novartis, Kite/Gilead, Actinium Pharmaceuticals, Amgen, Amneal Pharmaceuticals, Anthem, Bluebird Bio, Bristol Myers Squibb, Chimerix, CSL Behring, Cyto-Sen Therapeutics, Daiichi Sankyo, Gamida Cell, GlaxoSmithKline, Mesoblast, Miltenyi Biotec, Neovii, Oncoimmune, Pfizer, Pharmacyclics, Regeneron, Sanofi, Seattle Genetics, Shire Javier Bolaños-MeadeOther Relationship: IncyteNo other potential conflicts of interest were reported.

Figures

FIG 1.
FIG 1.
OS, stratified by conditioning intensity. MAC, myeloablative conditioning; OS, overall survival; RIC, reduced-intensity conditioning.
FIG 2.
FIG 2.
aGVHD by strata. aGVHD, acute graft-versus-host disease; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning.
FIG 3.
FIG 3.
cGVHD by strata. cGVHD, chronic graft-versus-host disease; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning.
FIG 4.
FIG 4.
Relapse or NRM by strata. MAC, myeloablative conditioning; NRM, nonrelapse mortality; RIC, reduced-intensity conditioning.
See this image and copyright information in PMC

Comment in

References

    1. Peters C, Schrappe M, von Stackelberg A, et al. Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors—The ALL-SCT-BFM-2003 trial J Clin Oncol 331265–12742015 - PubMed
    1. Saber W, Opie S, Rizzo JD, et al. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia Blood 1193908–39162012 - PMC - PubMed
    1. Besse K, Maiers M, Confer D, et al. On modeling human leukocyte antigen-identical sibling match probability for allogeneic hematopoietic cell transplantation: Estimating the need for an unrelated donor source Biol Blood Marrow Transplant 22410–4172016 - PubMed
    1. Gragert L, Eapen M, Williams EP, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry N Engl J Med 371339–3482014 - PMC - PubMed
    1. Dehn J, Spellman S, Hurley CK, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: Guidelines from the NMDP/CIBMTR Blood 134924–9342019 - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data